美迪西(688202)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
西部证券 2024-04-25 增持
长江证券 2024-02-25 买入
  盈利预测
据美迪西四季报分析:

  盈利能力明显恶化,总资产收益能力急剧下降

  成长能力明显恶化,营业收入由增长转为下降

  偿债能力维持稳定,即时支付现金能力大幅加强

  运营能力有所削弱,资产利用效率下降严重

  现金流能力有所加强,可持续经营能力加倍增强

  财务数据
    截至2024年第一季度实现净利润-0.38亿元,每股收益-0.28元。

    截至2024年第一季度最新股东权益245843.25万元,未分配利润65283.11万元。

    截至2024年第一季度最新总资产311491.61万元,负债65648.36万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入259,506,479.471,365,630,883.931,183,189,967.59872,326,588.54
营业总成本307,149,627.061,393,034,557.311,065,803,867.08687,706,554.52
营业利润-47,847,914.05-53,204,060.66119,659,284.83183,986,667.03
利润总额-48,313,515.56-59,104,955.81119,347,196.63183,826,016.58
净利润-37,555,731.42-33,210,603.1114,900,869.11166,132,438.94
其他综合收益125,481.28100,951.32381,612.47376,982.48
综合收益总额-37,430,250.14-33,109,651.78115,282,481.58166,509,421.42
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计1,701,960,383.171,876,189,651.052,217,016,933.671,302,712,457
非流动资产合计1,412,955,721.471,389,657,829.491,333,878,030.271,294,500,368.01
资产总计3,114,916,104.643,265,847,480.543,550,894,963.942,597,212,825.01
流动负债合计594,334,923.62686,359,970.17766,003,735.35755,126,472.16
非流动负债合计62,148,652.568,708,146.74114,208,233.18105,848,608.75
负债合计656,483,576.12755,068,116.91880,211,968.53860,975,080.91
归属于母公司股东权益合计2,458,432,528.522,510,779,363.632,670,682,995.411,736,237,744.1
股东权益合计2,458,432,528.522,510,779,363.632,670,682,995.411,736,237,744.1
负债和股东权益合计3,114,916,104.643,265,847,480.543,550,894,963.942,597,212,825.01
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计235,138,618.731,388,976,974.14982,573,416.08622,828,116.85
经营活动现金流出小计293,693,017.791,355,658,394.97991,342,424.7657,375,488.15
经营活动产生的现金流量净额-58,554,399.0633,318,579.17-8,769,008.62-34,547,371.3
投资活动现金流入小计256,129,890.04849,194,301.29426,713,927.7346,168,984.5
投资活动现金流出小计314,556,718.821,636,746,965.951,241,850,264.5172,720,703.37
投资活动产生的现金流量净额-58,426,828.78-787,552,664.66-815,136,336.77-126,551,718.87
筹资活动现金流入小计86,006,5001,464,092,170.621,420,755,063.15311,000,000
筹资活动现金流出小计131,298,188.38434,326,151.47262,685,025.51160,994,586.1
筹资活动产生的现金流量净额-45,291,688.381,029,766,019.151,158,070,037.64150,005,413.9
汇率变动对现金及现金等价物的影响1,437,310.88-187,413.741,955,557.662,167,502.61
现金及现金等价物净增加额-160,835,605.33275,344,519.92336,120,249.91-8,926,173.66
期末现金及现金等价物余额310,534,580.34471,370,185.67532,145,915.66187,099,492.09
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至2024年第一季度实现净利润-0.38亿元,每股收益-0.28元。

    截至2024年第一季度最新股东权益245843.25万元,未分配利润65283.11万元。

    截至2024年第一季度最新总资产311491.61万元,负债65648.36万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入259,506,479.471,365,630,883.931,183,189,967.59872,326,588.54
营业总成本307,149,627.061,393,034,557.311,065,803,867.08687,706,554.52
营业利润-47,847,914.05-53,204,060.66119,659,284.83183,986,667.03
利润总额-48,313,515.56-59,104,955.81119,347,196.63183,826,016.58
净利润-37,555,731.42-33,210,603.1114,900,869.11166,132,438.94
其他综合收益125,481.28100,951.32381,612.47376,982.48
综合收益总额-37,430,250.14-33,109,651.78115,282,481.58166,509,421.42
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计1,701,960,383.171,876,189,651.052,217,016,933.671,302,712,457
非流动资产合计1,412,955,721.471,389,657,829.491,333,878,030.271,294,500,368.01
资产总计3,114,916,104.643,265,847,480.543,550,894,963.942,597,212,825.01
流动负债合计594,334,923.62686,359,970.17766,003,735.35755,126,472.16
非流动负债合计62,148,652.568,708,146.74114,208,233.18105,848,608.75
负债合计656,483,576.12755,068,116.91880,211,968.53860,975,080.91
归属于母公司股东权益合计2,458,432,528.522,510,779,363.632,670,682,995.411,736,237,744.1
股东权益合计2,458,432,528.522,510,779,363.632,670,682,995.411,736,237,744.1
负债和股东权益合计3,114,916,104.643,265,847,480.543,550,894,963.942,597,212,825.01
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计235,138,618.731,388,976,974.14982,573,416.08622,828,116.85
经营活动现金流出小计293,693,017.791,355,658,394.97991,342,424.7657,375,488.15
经营活动产生的现金流量净额-58,554,399.0633,318,579.17-8,769,008.62-34,547,371.3
投资活动现金流入小计256,129,890.04849,194,301.29426,713,927.7346,168,984.5
投资活动现金流出小计314,556,718.821,636,746,965.951,241,850,264.5172,720,703.37
投资活动产生的现金流量净额-58,426,828.78-787,552,664.66-815,136,336.77-126,551,718.87
筹资活动现金流入小计86,006,5001,464,092,170.621,420,755,063.15311,000,000
筹资活动现金流出小计131,298,188.38434,326,151.47262,685,025.51160,994,586.1
筹资活动产生的现金流量净额-45,291,688.381,029,766,019.151,158,070,037.64150,005,413.9
汇率变动对现金及现金等价物的影响1,437,310.88-187,413.741,955,557.662,167,502.61
现金及现金等价物净增加额-160,835,605.33275,344,519.92336,120,249.91-8,926,173.66
期末现金及现金等价物余额310,534,580.34471,370,185.67532,145,915.66187,099,492.09
  十大流通股东
十大流通股东 报告期:2024-03-31
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
陈金章1636.2813.34-269.35
陈春来795.716.490.00
王国林639.165.210.00
林长青547.374.460.00
陈国兴487.523.980.00
CHEN CHUN-LIN404.223.300.00
MEDICILON INCORPORATED354.082.890.00
泽丰瑞熙私募证券基金管理(广东)有限公司-泽丰广鑫1号私募证券投资基金269.352.20269.35
全国社保基金四零六组合195.261.590.00
中国银行股份有限公司-华宝中证医疗交易型开放式指数证券投资基金177.101.448.90
  主力控盘
  公司简介
美迪西 所属地域: 上海市 涉及概念: 减肥药,创新药,CRO概念,沪股通,融资融券
主营业务: 爱滋病药物、抗癌药增敏剂、基因工程疫苗及生物医药中间体的研发,转让自有技术成果,并提供相关技术咨询、技术服务及自有技术的进出口,药用化合物、精细化学品(除危险化学品、监控化学品、烟花爆竹、民用爆炸物品、易制毒化学品)的研发、批发及进出口。【依法须经批准的项目,经相关部门批准后方可开展经营活动】。
上市日期: 2019-11-05 每股净资产: 18.25元 每股收益: -0.28元 净利润: -0.38亿元 净利润增长率: -136.98%
营业收入: 2.60亿元 每股现金流: -0.43元 每股公积金: 12.34元 每股未分配利润: 4.85元 总股本: 1.35亿 流通股: 1.23亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心